Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

Tissue biospecimens (TBs) are advantageous for profiling genetic disorders and are essential in developing molecular biology within contemporary medicine. Human TBs have aided the modern development ...

Solid tumors remain largely unresponsive to immune checkpoint inhibitors, in part due to their ability to suppress the cytotoxic activity of immune cells infiltrating the tumor microenvironment. One ...

WESTBURY, N.Y.--(BUSINESS WIRE)--BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will attend and sponsor the 8th Annual ...

This review summarizes the current landscape of ADC development, focusing on target selection and adverse impacts. It will guide future research to optimize the efficacy and safety of ADCs. ADCs are a ...

GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the ...

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...

The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its ...